120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
加味解郁合欢胶囊治疗卒中后抑郁：来自 DIA 蛋白质组学和 PRM 验证的见解
Authors Wang X, Gao Q, Liu C , Hu M, Liu Z, Li Z, Zhang H, Wu L, Chen K, Xu K, Geng X, Liu W, Wei S
Received 10 October 2025
Accepted for publication 23 January 2026
Published 4 February 2026 Volume 2026:20 565281
DOI https://doi.org/10.2147/DDDT.S565281
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Tuo Deng
Xinyu Wang,1– 5,* Qian Gao,6,* Chao Liu,7,8,* Minghui Hu,1,2 Zhiyao Liu,1,2,4 Zifa Li,1– 5 Hao Zhang,1– 4 Lidan Wu,1– 4 Kai Chen,9 Kaiyong Xu,2– 5 Xiwen Geng,1– 5 Wei Liu,1– 4,10 Sheng Wei1– 4
1Institute for Chinese Medicine and Brain Science, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 2Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 3Shandong Key Laboratory of Innovation and Application Research in Basic Theory of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 4Shandong Provincial Engineering Research Center for the Prevention and Treatment of Major Brain Diseases with Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 5Experimental Center, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 6Department of Basic Medical Sciences, Shijiazhuang Medical College, Shijiazhuang, Hebei, People’s Republic of China; 7Department of Traditional Chinese Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji’nan, Shandong, People’s Republic of China; 8First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China; 9Shandong Innovation Center of Engineered Bacteriophage Therapeutics, Shandong Academy of Pharmaceutical Sciences, Ji’nan, Shandong, People’s Republic of China; 10Department of Encephalopathy, The second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Sheng Wei, Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China, Fax +86 531 89628015, Email weisheng@sdutcm.edu.cn Wei Liu, Department of Encephalopathy, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China, Email Lw_1369@163.com
Background and Purpose: Post-stroke depression (PSD), a prevalent neuropsychiatric complication of stroke, manifests as persistent low mood and depressive symptoms secondary to cerebrovascular injury, contributing to increased morbidity and mortality. Although the modified Jie-Yu-He-Huan (MJYHH) capsule has demonstrated clinical efficacy in alleviating PSD symptoms, its pharmacological targets and mechanisms of action remain unclear.
Methods: Pharmacological screening was performed on healthy C57BL/6 mice, revealing significant antidepressant effects of MJYHH. A PSD rat model was subsequently established through combined middle cerebral artery occlusion (MCAO), social isolation, and chronic mild stress (CMS). Behavioural tests were conducted to evaluate therapeutic outcomes. Data-independent acquisition (DIA) and parallel reaction monitoring (PRM) technologies were employed to investigate the traditional Chinese medicine (TCM) mechanisms.
Results: The PSD model group exhibited characteristic depressive behaviours, which were significantly attenuated by MJYHH treatment. Proteomic analysis identified 16 differentially expressed proteins (DEPs), with subsequent Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) network analyses demonstrating their predominant association with: biosynthetic and metabolic pathways, oxidative stress response, mitochondrial dysfunction.PRM validation and molecular docking studies further implicated three key targets (Rrm2b, Cyp51a1, and Rhot2) as potential mediators of MJYHH’s therapeutic effects.
Conclusion: This integrated investigation combining animal models, omics technologies, and computational approaches elucidates the multi-target mechanism of MJYHH capsule in PSD treatment, providing a scientific foundation for TCM-based intervention strategies.
Keywords: post-stroke depression, modified Jie-Yu-He-Huan capsules, data independent acquisition, parallel reaction monitoring, molecular docking
1Institute for Chinese Medicine and Brain Science, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 2Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 3Shandong Key Laboratory of Innovation and Application Research in Basic Theory of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 4Shandong Provincial Engineering Research Center for the Prevention and Treatment of Major Brain Diseases with Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 5Experimental Center, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, 250355, People’s Republic of China; 6Department of Basic Medical Sciences, Shijiazhuang Medical College, Shijiazhuang, Hebei, People’s Republic of China; 7Department of Traditional Chinese Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji’nan, Shandong, People’s Republic of China; 8First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China; 9Shandong Innovation Center of Engineered Bacteriophage Therapeutics, Shandong Academy of Pharmaceutical Sciences, Ji’nan, Shandong, People’s Republic of China; 10Department of Encephalopathy, The second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Sheng Wei, Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China, Fax +86 531 89628015, Email weisheng@sdutcm.edu.cn Wei Liu, Department of Encephalopathy, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji’nan, Shandong, People’s Republic of China, Email Lw_1369@163.com
Background and Purpose: Post-stroke depression (PSD), a prevalent neuropsychiatric complication of stroke, manifests as persistent low mood and depressive symptoms secondary to cerebrovascular injury, contributing to increased morbidity and mortality. Although the modified Jie-Yu-He-Huan (MJYHH) capsule has demonstrated clinical efficacy in alleviating PSD symptoms, its pharmacological targets and mechanisms of action remain unclear.
Methods: Pharmacological screening was performed on healthy C57BL/6 mice, revealing significant antidepressant effects of MJYHH. A PSD rat model was subsequently established through combined middle cerebral artery occlusion (MCAO), social isolation, and chronic mild stress (CMS). Behavioural tests were conducted to evaluate therapeutic outcomes. Data-independent acquisition (DIA) and parallel reaction monitoring (PRM) technologies were employed to investigate the traditional Chinese medicine (TCM) mechanisms.
Results: The PSD model group exhibited characteristic depressive behaviours, which were significantly attenuated by MJYHH treatment. Proteomic analysis identified 16 differentially expressed proteins (DEPs), with subsequent Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) network analyses demonstrating their predominant association with: biosynthetic and metabolic pathways, oxidative stress response, mitochondrial dysfunction.PRM validation and molecular docking studies further implicated three key targets (Rrm2b, Cyp51a1, and Rhot2) as potential mediators of MJYHH’s therapeutic effects.
Conclusion: This integrated investigation combining animal models, omics technologies, and computational approaches elucidates the multi-target mechanism of MJYHH capsule in PSD treatment, providing a scientific foundation for TCM-based intervention strategies.
Keywords: post-stroke depression, modified Jie-Yu-He-Huan capsules, data independent acquisition, parallel reaction monitoring, molecular docking